Chimeric: Media Thread, page-303

Eliot Bourke and panel speak at length about business and pipeline strategies in CAR-T biotechs.

Interesting to note is the discussion at 19:40 of the relationships between these CAR-T biotechs, and the sharemarket, particularly the difficulty in attracting investors in a 'Crowded Market'. Including de-resking strategies etc.,.

Moderator: Michael C. Rice, MS, MBA, SVP, BioConsulting, Advanced Therapeutics and Rare Diseases, Lumanity

Panelists:

• Gregory Block, PhD, Senior Vice President, Corporate Development, Notch Therapeutics
• Eliot Bourk, PhD, Chief Business Officer and Head of External Innovation, Chimeric Therapeutics
• David C. White, PhD, CEO, Modulari-T Biosciences
• Paul D. Rennert, President & CSO, Aleta Biotherapeutics

A company’s product portfolio should tell the story about how well leadership understands its value proposition and has set about de-risking what may be transformative but as yet unproven technology. The need to systemically de-risk becomes particularly pressing when building upon validated approaches with unique or multiplexed engineering of cell therapy candidates. Advancing through a series of increasingly sophisticated clinical candidates can be done too slowly or too quickly, and the markets make their determination only with the benefit of hindsight. Regardless, R&D must be informed by a forward-looking positioning strategy, and we will discuss some of the key considerations to adopt and pitfalls to avoid when advancing novel engineering components or combinations thereof.